Canada: Trade Secrets

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

In recent years, local trademarks and products have been attracting growing interest from consumers. This trend can be explained by the ability of local players to better understand...

Depuis quelques années, les marques et produits locaux suscitent un intérêt croissant auprès des consommateurs. Cette tendance s'explique notamment par la capacité des acteurs...

What happens to the copyright of your works when you die? After a lifetime of creative output, artists, authors, musicians and other creators alike may wish to think about the legacy they are leaving behind.

In part one of our IP licensing primer series, we broached the concept of IP licensing and explained how the type of IP...

Intellectual property is a key asset of most businesses, yet IP rights are often underutilized or misunderstood as a business asset.

With the year well underway, it's an opportune time to examine the emerging and expected trends in 2025 for licensing partnerships in the life sciences industry.

In Alexion Pharmaceuticals v Amgen, the Federal Court upheld the validity of Alexion's eculizumab patent (CA810), rejecting Amgen's claims of anticipation and obviousness...

En réponse directe aux commentaires reçus et à l'évolution des besoins des entreprises d'innovation de l'Ontario en matière de propriété intellectuelle, Propriété intellectuelle Ontario (PIO) a annoncé deux...

This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access—since our March 2024 update.